$BIVI News

BioVie Files Prospectus To Offer Up To $300M In Securities

BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript

BioVie: Long COVID trial fully enrolled – ICYMI

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

BioVie completes enrollment in Long COVID trial as need for treatments grows

BioVie completes enrollment in Phase 2 Long COVID trial

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID

BioVie completes final patient visit in Parkinson's drug trial

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's Disease

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology Transcript

BioVie CEO shares insights into long COVID trial - ICYMI

BioVie advances long COVID trial, top-line data expected by summer

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie To Host Virtual Key Opinion Leader Event On May 7 To Discuss Phase 2 Trial Of Bezisterim To Treat Parkinson's Disease

RedChip's Biotech Investor Conference Replays Now Available

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie abstract on Parkinson’s drug accepted for neurology conference

BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI